Wouters Olivier J, Kanavos Panos G
LSE Health, London School of Economics and Political Science, Houghton Street, London, WC2A 2AE, UK.
BMC Health Serv Res. 2017 Mar 31;17(1):242. doi: 10.1186/s12913-017-2184-5.
Policymakers and researchers frequently compare the prices of medicines between countries. Such comparisons often serve as barometers of how pricing and reimbursement policies are performing. The aim of this study was to examine methodological challenges to comparing generic drug prices.
We calculated all commonly used price indices based on 2013 IMS Health data on sales of 3156 generic drugs in seven European countries.
There were large differences in generic drug prices between countries. However, the results varied depending on the choice of index, base country, unit of volume, method of currency conversion, and therapeutic category. The results also differed depending on whether one looked at the prices charged by manufacturers or those charged by pharmacists.
Price indices are a useful statistical approach for comparing drug prices across countries, but researchers and policymakers should interpret price indices with caution given their limitations. Price-index results are highly sensitive to the choice of method and sample. More research is needed to determine the drivers of price differences between countries. The data suggest that some governments should aim to reduce distribution costs for generic drugs.
政策制定者和研究人员经常比较不同国家间药品的价格。此类比较常常作为定价和报销政策实施情况的晴雨表。本研究的目的是探讨比较仿制药价格时在方法上所面临的挑战。
我们基于艾美仕市场研究公司(IMS Health)2013年关于七个欧洲国家3156种仿制药销售情况的数据,计算了所有常用的价格指数。
各国之间仿制药价格存在巨大差异。然而,结果会因指数的选择、基准国家、销量单位、货币换算方法以及治疗类别而有所不同。结果还因是查看制造商所收取的价格还是药剂师所收取的价格而有所差异。
价格指数是比较各国药品价格的一种有用的统计方法,但鉴于其局限性,研究人员和政策制定者在解读价格指数时应谨慎。价格指数结果对方法和样本的选择高度敏感。需要开展更多研究以确定各国间价格差异的驱动因素。数据表明,一些政府应致力于降低仿制药的分销成本。